Moderna news - the latest news from Labiotech.eu

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Jim Cornall — Thu, 23 Feb 2023 10:26:34 +0000

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

The post Moderna and Life Edit Therapeutics look to speed up gene editing therapies appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Liza Laws — Fri, 26 Aug 2022 14:32:12 +0000

Moderna is today (August 26) filing patent infringement lawsuits against Pfizer and its partner BioNTech in both the U.S and Germany. The mRNA-focused biotech claims the companies’ Covid-19 vaccine Comirnaty infringes patents it led between 2010 and 2016 covering Moderna’s foundational mRNA technology which the company says was critical to the development of its own […]

The post Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology” appeared first on Labiotech.eu.

IVI and Moderna sign MOU for vaccine R&D

Jim Cornall — Wed, 20 Jul 2022 15:49:02 +0000

The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Moderna, a biotech company working on messenger RNA (mRNA) therapeutics and vaccines, have signed a Memorandum of Understanding (MOU) to partner on collaborative vaccine research and development. “IVI welcomes this […]

The post IVI and Moderna sign MOU for vaccine R&D appeared first on Labiotech.eu.

The COVID-19 pandemic has driven RNA therapeutics into the mainstream

Helen Albert — Mon, 04 Jul 2022 08:42:56 +0000

As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […]

The post The COVID-19 pandemic has driven RNA therapeutics into the mainstream appeared first on Labiotech.eu.

Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans

Helen Albert — Wed, 29 Apr 2020 14:20:23 +0000

Update (29/04/2020): A vaccine developed by the German company BioNTech and its big pharma partner Pfizer has become the first European mRNA vaccine for Covid-19 to enter human testing in a phase I/II trial. Since dosing began last week, twelve volunteers in Germany have been given the vaccine. The first part of the trial — […]

The post Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans appeared first on Labiotech.eu.

Coronavirus Pandemic Bites into European Cancer Research

Anita Chakraverty — Fri, 10 Apr 2020 07:30:36 +0000

The UK funder Cancer Research UK and Swedish oncology biotech Alligator Bioscience have independently announced cuts to payroll and research costs due to the coronavirus disease pandemic. Cancer Research UK is cutting research funding by €50M after calculating it will lose a quarter or more of its annual fundraising income — or €137m — through […]

The post Coronavirus Pandemic Bites into European Cancer Research appeared first on Labiotech.eu.

Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?

Jonathan Smith — Mon, 30 Mar 2020 17:31:36 +0000

The first vaccine against coronavirus disease could one day be made of mRNA. How is mRNA showing promise against the pandemic, and what could it signify for the mRNA field? The global number of coronavirus disease (Covid-19) cases has passed 600,000 and is threatening to bring healthcare systems worldwide to their knees. To control the […]

The post Could mRNA Vaccines Fulfill Their Potential Against Coronavirus? appeared first on Labiotech.eu.

Bored Between the Holidays? Watch these Biotech Videos!

Evelyn Warner — Thu, 28 Dec 2017 11:00:19 +0000

Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are our highlights from 2017. It’s vacation time! If you’ve worn out the holiday movies, catch up on our biotech ones. It was a busy year, and we produced a lot, thanks to our new Hangouts […]

The post Bored Between the Holidays? Watch these Biotech Videos! appeared first on Labiotech.eu.

US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine

Clara Rodríguez Fernández — Wed, 15 Nov 2017 14:50:10 +0000

Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […]

The post US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine appeared first on Labiotech.eu.

Battle of the Biotech Unicorns: CureVac vs. Moderna

Clara Rodríguez Fernández — Mon, 06 Nov 2017 06:00:02 +0000

An interview never seen before. We brought together the founders and CEOs of the two biotech unicorns pioneering mRNA therapy: CureVac in Germany and Moderna Therapeutics in the US. The idea of messenger RNA as a therapy is simple but brilliant: instead of giving a protein to a patient, you give their body the instructions […]

The post Battle of the Biotech Unicorns: CureVac vs. Moderna appeared first on Labiotech.eu.

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

Clara Rodríguez Fernández — Thu, 02 Nov 2017 09:31:30 +0000

AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […]

The post AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure appeared first on Labiotech.eu.

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

Clara Rodríguez Fernández — Tue, 19 Sep 2017 05:00:35 +0000

You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that some believe could be as big a revolution as monoclonal antibodies. For a long time after the discovery of nucleic acids, now almost 150 years […]

The post RNA as a Therapy: Reviewing the Future Generation of Therapeutics appeared first on Labiotech.eu.

Way to Success: What Role does Company Culture Play in Biotech?

Clara Rodríguez Fernández — Wed, 17 May 2017 06:00:24 +0000

You’ve surely heard how great company culture is the key to the success of tech giants Google and Facebook. Does it also apply to biotech companies? Company culture is what drives employees to give their best every day for a cause they believe in. It’s what makes the best stay loyal to a firm over […]

The post Way to Success: What Role does Company Culture Play in Biotech? appeared first on Labiotech.eu.

What are the Best Countries to Recruit Biotech Talents in 2017?

External Contributor — Wed, 15 Mar 2017 07:00:27 +0000

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […]

The post What are the Best Countries to Recruit Biotech Talents in 2017? appeared first on Labiotech.eu.

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Clara Rodríguez Fernández — Mon, 26 Dec 2016 07:00:06 +0000

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

The post The Largest Deals, Fundraising and Exits of 2016 in European Biotech appeared first on Labiotech.eu.

mRNA Money-magnet increases its Pile of Cash to over €1.3Bn

Denise Neves Gameiro — Fri, 12 Aug 2016 10:00:57 +0000

Moderna is taking Biotech investing to new heights, as it has now increased total fundraising&partnership cash to an unbelievable €1.34Bn ($1.5Bn). It can thank AstraZeneca, which is now adding €126M more to its investment. Amid dropping revenues and pipeline cuts, AstraZeneca remains steadily focused on innovation and Biotech. After all, this was the strategy CEO Pascal […]

The post mRNA Money-magnet increases its Pile of Cash to over €1.3Bn appeared first on Labiotech.eu.

AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease

Denise Neves Gameiro — Wed, 27 Jul 2016 12:27:50 +0000

The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for cardiometabolic diseases. Therapies using mRNA have a lot of potential as biologics. Leading Biotechs in the field include CureVac (interview with its CCO here) and […]

The post AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease appeared first on Labiotech.eu.

The Biotech World is Buzzing: J.P. Morgan’s 2016 Phenomenon Kicks off this Week!

Philip Hemme — Thu, 14 Jan 2016 14:09:08 +0000

Imagine a conference where all the Biotech CEOs and investors of the World come together…all the major players in this Industry, under one roof. That’s basically what the J.P.Morgan Conference is about. Organized by the banking firm of the same name, it is the 34th edition this year. And with age, comes exclusivity: The J.P. […]

The post The Biotech World is Buzzing: J.P. Morgan’s 2016 Phenomenon Kicks off this Week! appeared first on Labiotech.eu.

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

Jerome Topsent — Tue, 05 Jan 2016 09:48:03 +0000

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

The post Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine? appeared first on Labiotech.eu.

What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field?

Dani Bancroft — Tue, 17 Nov 2015 15:58:50 +0000

The Microbiome and Immuno-Oncology fields are hugely trendy in the Biotech Industry – and now a marriage between the two has finally occurred… The Microbiome field is still very new, with the launch of the US Human Microbiome Project just happening in 2008. Nonetheless, some start-ups are moving fast up the microbiome ranks, as well […]

The post What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field? appeared first on Labiotech.eu.